Search

Your search keyword '"Ndrepepa, Gjin"' showing total 7 results
Start Over Author "Ndrepepa, Gjin" Publisher american medical association
7 results on '"Ndrepepa, Gjin"'

1. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial

Author

Schomig, Albert, Mehilli, Julinda, Antoniucci, David, Ndrepepa, Gjin, Markwardt, Christina, Pache, Jurgen, Seyfarth, Melchior, Martinoff, Stefan, Schuhlen, Helmut, Benzer, Werner, Schlotterbeck, Klaus, Schmitt, Claus, Nekolla, Stephan G., Dirschinger, Josef, Pede, Francesco Di, Schwaiger, Markus, and Astrati, Adnan

Subjects
Cardiovascular instruments, Implanted -- Usage, Abciximab -- Health aspects, Infarction -- Health aspects, Reperfusion (Physiology) -- Health aspects, Heart attack -- Care and treatment, Clinical trials
Abstract

A study aims to assess whether an immediate invasive treatment strategy is associated with a reduction of infarct size in patients with acute St-segment elevation myocardial infarction (STEMI), presenting between 12 and 48 hours after symptom onset, vs. a conventional conservative strategy. An invasive strategy based on coronary stenting with adjunctive use of abciximab reduces infarct size in patients with acute STEMI without persistent symptoms presenting 12 to 48 hours after symptom onset.

Published
2005

2. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

Author

Coughlan, J. J., Aytekin, Alp, Lahu, Shqipdona, Ndrepepa, Gjin, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Gewalt, Senta, Witzenbichler, Bernhard, Hochholzer, Willibald, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Hemetsberger, Rayyan, Valina, Christian, Müller, Arne, Kufner, Sebastian, Liebetrau, Christoph, and Xhepa, Erion

Published
2021
Full Text
View/download PDF

3. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

Author

Mayer, Katharina, Hein-Rothweiler, Ralph, Schüpke, Stefanie, Janisch, Marion, Bernlochner, Isabell, Ndrepepa, Gjin, Sibbing, Dirk, Gori, Tommaso, Borst, Oliver, Holdenrieder, Stefan, Kupka, Danny, Petzold, Tobias, Bradaric, Christian, Okrojek, Rainer, Leistner, David M., Trippel, Tobias D., Münzel, Thomas, Landmesser, Ulf, Pieske, Burkert, and Zeiher, Andreas M.

Published
2021
Full Text
View/download PDF

4. Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock.

Author

Ndrepepa, Gjin, Schömig, Albert, and Kastrati, Adnan

Subjects
*NITRIC oxide, *CARDIOGENIC shock, *THERAPEUTICS, *HEART diseases, *CORONARY heart disease treatment, MYOCARDIAL infarction-related mortality
Abstract

The article presents an editorial that discusses a lack of benefit associated with the inhibition of nitric oxide synthase in patients with cardiogenic shock complicating acute myocardial infarction (MI). The results of a randomized controlled study, called the Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock, are reported in the current issue and discussed in this editorial. The mortality rates of patients with cardiogenic shock are discussed.

Published
2007
Full Text
View/download PDF

5. Need for Critical Reappraisal of Intra-aortic Balloon Counterpulsation.

Author

Ndrepepa, Gjin and Kastrati, Adnan

Subjects
*INTRA-aortic balloon counterpulsation, *MYOCARDIAL infarction treatment, *CARDIOGENIC shock, *HEART diseases, *THERAPEUTICS, *INFARCTION
Abstract

The article emphasizes the need to reevaluate the use of intra-aortic balloon counterpulsation (IABC) for stent thrombosis (ST)-segment elevation myocardial infarction (STEMI) with cardiogenic shock and percutaneous coronary intervention (PCI). It references the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction (CRISP AMI) trial by M. R. Patel et al. published within the issue. The authors explain the impact of IABC on infarct size and patient outcomes.

Published
2011
Full Text
View/download PDF

6. Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms.

Author

Ndrepepa, Gjin, Kastrati, Adnan, Mehilli, Julinda, Antoniucci, David, and Schömig, Albert

Subjects
*LETTERS to the editor, *MYOCARDIAL infarction treatment
Abstract

A research letter is presented which examines the association between mechanical reperfusion and long-term mortality in patients presenting 12 to 48 hours after the onset of symptoms of acute myocardial infarction.

Published
2009
Full Text
View/download PDF

7. Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction—Reply.

Author

Schömig, Albert, Ndrepepa, Gjin, and Kastrati, Adnan

Subjects
*LETTERS to the editor, *REPERFUSION
Abstract

The article presents a reply from the authors to letters to the editor in response to the article "Beyond 12 hours Reperfusion Alternative Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial," by A. Schömig, J. Mehiilli, and D. Antoniucci in 293: 2865-2872.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results